Objective: To evaluate the available evidence regarding the efficacy and safety of rifampicin,
as adjunct to colistin, in the treatment of multidrug resistant Acinetobacter baumannii (MDR …

The existence of infections caused by multidrug resistant (MDR) Acinetobacter baumannii is
a growing problem because of the difficulty to treat them. We examined the published …

Combination therapy may be required for multidrug-resistant (MDR) Acinetobacter
baumannii. This study systematically investigated bacterial killing and emergence of colistin …

Acinetobacter baumannii remains a difficult-to-treat pathogen that poses a significant
challenge to clinicians and costs to the healthcare system. There is a lack of clinical efficacy …

(1) Introduction: Colistin combination therapy with other antibiotics is a way to enhance
colistin activity. The purpose of this meta-analysis was to compare the efficacy and safety of …

Background. Extensively drug-resistant (XDR) Acinetobacter baumannii may cause serious
infections in critically ill patients. Colistin often remains the only therapeutic option. Addition …

Objectives The increased incidence of nosocomial infections by multidrug-resistant
organisms has motivated the re-introduction of colistin in combination with other …

Evaluation of: Colistin and Rifampicin compared with colistin alone for the treatment of
serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter …

Objectives: We aimed to assess the efficacy and safety of a high loading dose of colistin and
no loading dose of colistin to treat multidrug-resistant (MDR) Acinetobacter baumannii …

We have observed previously that rifampicin is active in vitro against A. baumannii, and this
led us to investigate the potential therapeutic role of this antimicrobial agent in combination …